Diagnostic and therapeutic evaluation of an anti-Langerhans cell histiocytosis monoclonal antibody (NA1/34) in a new xenograft model

Journal of Investigative Dermatology

Volumn 114, Issue 1, 2000, Pages 127-134

  Murray, Samuel ^a,c   Rowlinson Busza, Gail ^b,d   Morris, Jenny F ^a   Chu, Anthony C ^a  

^a Unit of Dermatology   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

CD1a; Langerhans cell histiocytosis cells; Radioimmunoscintigraphy; Radioimmunotherapy

Indexed keywords

ANTIBODY DETECTION; ARTICLE; DIFFERENTIAL DIAGNOSIS; HISTIOCYTOSIS X; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SCINTIGRAPHY; XENOGRAFT;

EID: 0034129021     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.2000.00831.x     Document Type: Article

References (42)

1. Begent RH, Verharr HJ, Chester KA, et al: Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nature Med 2:979-998, 1996
2. Buchbaum DJ, Sinkule JA, Stites MS, et al: Localization and imaging with radioiodine-labeled monoclonal antibodies in a xenogeneic tumor model for human B-cell lymphoma. Cancer Res 48:2475-2482, 1988
3. 2 fragments. J Clin Invest 83:1449-1456, 1989
4. Burns BF, Colby TV, Dorfman RF: Langerhans cell granulomatosis (histiocytosis X) associated with malignant lymphomas. Am J Surg Pathol 7:529-533, 1983
5. Burtnick LD: Modification of actin with fluorescein isothiocyanate. Biochem Biophys Acta 791:57-62, 1984
6. Ceci A, de-Terlizzi M, Colella R, et al: Langerhans cell histiocytosis in childhood: results from the Italian Co-operative AIEOP-CNR-H.X '83 Study. Med Pediatr Oncol 21:259-264, 1993
7. Chiou RK: The impact of tumour size on the efficacy of monoclonal antibody-targeted radiotherapy: Studies using a nude mouse model with human renal cell carcinoma xenografts. J Urol 46:132-237, 1991
8. Chu AC: Histiocytoses. In: Champion RH, et al (eds). Textbook of Dermatology, 5th edn. Oxford: Blackwell Scientific Publications, 1992, pp 2041-2064
9. Chu AC, Eisinger M, Lee JS, Takezaki S, Kung PC, Edelson RL: Immunoelectomicroscopic identification of Langerhans cells using a new antigenic marker. J Invest Dermatol 78:177-180, 1982
10. Eagle H: Propagation in fluid medium of a human epidermoid carcinoma strain KB. Prof Soc Exp Biol Med 89:362-364, 1955
11. Egeler RM, Neglia JP, Puccetti DM, Brennan CA, Nesbit ME: Association of Langerhans cell histiocytosis with malignant neoplasms. Cancer 71:865-873, 1993
12. Fraker PJ, Speck JC Jr: Protein and cell membrane iodinations with a sparingly soluble chloramide, 1,3,4,6-tetrachloro-3a, 6a-diphenylglycoluril. Biochem Biophys Res Commun 80:849-857, 1978
13. Fujita M, Horiguchi Y, Miyachi Y, Furukawa F, Kashihara-Sawam M, Imamura S: A subpopulation of Langerhans cells (CD1a+Lag-) increased in the dermis of plaque lesions of mycosis fungoides. J Am Acad Dematol 25:491-499, 1991
14. 99mTc. Cancer Res 50:909s-921s, 1990
15. Greenberger JS, Crocker AC, Vawter G, Jaffe N, Cassady JR: Results of treatment of 127 patients with systemic histiocytosis (Letterer-Siwe syndrome, Schuller-Christian syndrome and multifocal eosinophilic granuloma). Medicine 60:311-337, 1981
16. Groh V, Gadner H, Radaszkiewicz T, Rappersberger K, Konrad K, Wolff K, Stingl G: The phenotypic spectrum of histiocytosis X cells. J Invest Dermatol 90:441-447, 1988
17. Hanau D, Fabre M, Schmitt DA, et al: Human epidermal Langerhans cells internalise by receptor-mediated endocytosis T6 (CD1a NA1/34) surface antigen. Birbeck granules are involved in the intracellular traffic of the T6 antigen. J Invest Dermatol 89:172-177, 1987
18. Hertel A, Baum RP, Lorenz M, Baew-Christow T, Encke A, Hor G: Immunoscintigraphy using a technetium-99m labelled monoclonal anti-CEA antibody in the follow up of colorectal cancer and other tumours producing CEA. Br J Cancer 10(Suppl.):34-36, 1990
19. HMSO: Guidance on the Operation of the Animals (Scientific Procedures) Act, 1986. London: HMSO, 1986
20. Hnatowich DJ, Layne WW, Childs RL, Lanteigne O, Davis MA: Radioactive labelling of antibody: a simple and efficient method. Science 220:613-615, 1983
21. 99mTc anti NCA monoclonal antibodies for imaging inflammation. Eur J Nucl Med 14:367-373, 1988
22. Komp DM: Langerhans cell histiocytosis (Editorial). N Engl J Med 316:714-748, 1987
23. Ladisch S, Gadner H: Treatment of Langerhans cell histiocytosis - evolution and current approaches. Br J Cancer 70(Suppl. XXIII):S41-S46, 1994
24. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA: Determination of the immunoreactive fraction of radiolabelled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 72:77-89, 1984
25. Longley J, Kraus J, Alonso M, Edelson R: Molecular cloning of CD1a (T6), a human epidermal dendritic cell marker related to class I MHC molecules. J Invest Dermatol 92:628-631, 1989
26. Misery L, Campos L, Dezutter-Dambuyant C, Guyotat D, Treille D, Schmitt D, Thivolet J: CD1-reactive leukaemic cells in bone marrow: presence of Langerhans cell marker on leukaemic monocytic cells. Eur J Haematol 48:27-32, 1992
27. Morgan G: Myeloablative therapy and bone marrow transplantation for Langerhans cell histiocytosis. Br J Cancer 70:(Suppl. XXIII):S52-S53, 1994
28. Nezelof C, Bassel F, Rousseau MF: Histiocytosis X: histogenic arguments for a Langerhans cell origin. Biomedicine 18:365-371, 1973
29. Nezelof C, Frileux-Herbert F, Cronier-Sachot J: Disseminated histiocytosis X. Analysis of prognostic factors based on a retrospective study of 50 cases. Cancer 44:1824-1838, 1979
30. Pelleitier M, Montplaisir S: The nude mouse: a model of deficient T-cell function. Methods Achiev Exp Pathol 7:149-166, 1975
31. Press OW, Eary JF, Appelbaum FR, et al: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 325:1219-1224, 1993
32. Reilly RM, Sandhu J, Alvarez-diez TM, Gallinger S, Kirsh J, Stern H: Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions. Clin Pharmacokinet 28:126-142, 1995
33. Scheinberg DA, Lovett D, Digvi CR, et al: A phase I trial of monoclonal antibody M195 in acute myelogenous leukaemia: Specific bone marrow targeting and intenalisation of the radionuclide. J Clin Oncol 9:478-490, 1991
34. Scherer WF, Syverton JT, Gey GO: Studies on the propagation in vitro of poliomyelitis viruses IV. Viral multiplication in a stable strain of human malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the cervix. J Exp Med 97:695-709, 1953
35. Schlom J, Molinolo A, Simpson JF, et al: Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. J Natl Cancer Inst 82:763-771, 1990
36. Schroff RS, Foon KA, Beatty SM, Oldham RK, Morgan AC Jr: Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 45:879-885, 1985
37. Siler K, Eggensperger D, Hand PH, et al: Therapeutic efficacy of a high-affinity anticarcinoembryonic antigen monoclonal antibody (COL-1). Biotechnol Ther 4:163-181, 1993
38. Toolan HW: Transplantable human neoplasms maintained in cortisone-treated laboratory animals. H.S.#1; H.Ep.#1; H.Ep.#2; H.Ep.#3; and H.Emb. Rh.#1. Cancer Res 14:660-666, 1954
39. Vriesendorp HM, Herpst JM, Germack MA, Klein JL, Leichner PK, Loudenslanger DM, Order SE: Phase I-II studies of yttrium-labeled anti-ferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01. J Clin Oncol 9:918-928, 1991
40. Writing Group of the Histiocyte Society. Histiocytosis syndromes in children. Lancet i:208-209, 1987
41. Yokota T, Milenic DE, Whitlow M, Schlom J: Rapid penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 52:3402-3408, 1992
42. Yu RC, Chu C, Buluwela L, Chu AC: Clonal proliferation of Langerhans cells in Langerhans cell histiocytosis. Lancet 343:767-768, 1994